Products

RECURSION
Recursion Pharmaceuticals
Drug Discovery & Research
Recursion Pharmaceuticals is a clinical-stage TechBio company focused on decoding biology to industrialize drug discovery through its AI-native, end-to-end platform, the Recursion OS.

See all 1 product →

About Recursion Pharmaceuticals

Recursion is an AI-driven drug discovery and development company focused on uncovering novel medicines. The company utilizes a platform that integrates disease-specific cellular engineering, unbiased high-dimensional biology, and supercompute-powered foundation models. This approach aims to accelerate the identification and development of potential new medicines, particularly in areas with high unmet medical need such as oncology and rare diseases.

The company’s end-to-end learning system, described as a “lab-in-the-loop,” combines physical automation and machine learning models. This system connects biology, precision design, and translational clinical tools to systematically de-risk drug discovery. Recursion’s pipeline includes investigational medicines in various stages of development, from preclinical to Phase 1/2 clinical trials, targeting conditions like familial adenomatous polyposis, solid tumors, and hematologic malignancies.

Focus Areas

AI-driven drug discovery rare diseases oncology inflammation & immunology neuroscience precision medicine

Business Intelligence

TechnologyRecursion Operating System (OS), a full-stack, AI-native platform integrating automated wet labs, high-throughput cellular imaging (Cell Painting assay), deep learning, and a supercomputer (BioHive-2) to generate and analyze proprietary biological and chemical datasets (>60 petabytes).

What Physicians Need to Know

AI-Driven Drug Discovery
Recursion pioneers AI drug discovery and development, aiming to uncover novel medicines faster, better, and at scale. Their platform integrates disease-specific cellular engineering, unbiased high-dimensional biology, supercompute-powered foundation models, and an integrated Design-Make-Test-Learn approach.
Rare Diseases
Their wholly-owned pipeline includes potential new medicines in areas with high unmet need, such as rare diseases. The differentiation for each program is driven by their AI-enabled product engine, from novel biology to precision design to clinical development.
Oncology
Recursion has a diverse collection of potential new medicines in oncology within its pipeline. This includes programs like REC-1245 for solid tumors and lymphoma, REC-4539 for solid tumors and hematology oncology, and REC-7735 for solid tumors.
Inflammation & Immunology
While not explicitly detailed as a separate category, their platform is designed to address complex disease areas, and their AI-native product engine is applied to overcome specific therapeutic challenges, which can include those in inflammation and immunology.
Neuroscience
Recursion has achieved milestones in neuroscience, including unlocking the first neuroscience target for a collaboration with Genentech.
Precision Medicine
Their approach emphasizes precision design, utilizing their AI-enabled product engine to systematically de-risk drug discovery. This involves narrowing down millions of molecules to a synthetically accessible short list that is makeable before lab testing.
Key Differentiators
Recursion's key differentiators include their end-to-end learning system, which tightly connects biology, precision design, and translational clinical tools. They operate a 'lab-in-the-loop' system of physical automation and machine learning models, enabling continuous learning and rapid advancement of novel candidates with significantly fewer compounds synthesized compared to the industry average.
Technology Stack
Their technology stack involves disease-specific cellular engineering, unbiased high-dimensional biology, supercompute-powered foundation models, and an integrated Design-Make-Test-Learn cycle. This system is driven by global bilingual teams of scientists and technologists.
Physician Tip

Recursion's AI-driven platform aims to accelerate the discovery and development of novel medicines, potentially leading to new therapeutic options for patients in areas of high unmet need, including various cancers, rare diseases, and neurological conditions. Their focus on precision design and an integrated discovery process may result in more targeted and effective treatments. Physicians can anticipate a pipeline of differentiated investigational medicines that have undergone a rigorous, AI-enabled de-risking process.

Products by Recursion Pharmaceuticals

1 product in the directory

RECURSION
Recursion Pharmaceuticals
Drug Discovery & Research
Recursion Pharmaceuticals is a clinical-stage TechBio company focused on decoding biology to industrialize drug discovery through its AI-native, end-to-end platform, the Recursion OS.

Videos

News, demos, and interviews about Recursion Pharmaceuticals.

Loading videos...

Videos load interactively. If none appear, search YouTube for Recursion Pharmaceuticals →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

Recursion Pharmaceuticals focuses on AI-driven drug discovery and development to uncover novel medicines, particularly in areas with high unmet need like oncology and rare diseases.
The company targets various diseases, including familial adenomatous polyposis, solid tumors, lymphoma, hematology oncology, and hypophosphatasia.
Their AI-enabled product engine drives differentiation from novel biology to precision design and clinical development, aiming to de-risk drug discovery systematically.
Recursion Pharmaceuticals advances joint portfolios with pharma partners across complex disease areas, applying its AI-native product engine to overcome therapeutic challenges.
One example is REC-4881, a MEK1/2 inhibitor currently in Phase 1/2 clinical trials for Familial adenomatous polyposis.
They utilize an end-to-end learning system that tightly connects biology, precision design, and translational clinical tools, forming a continuous learning system of physical automation and machine learning models.

Investors

Who's funded Recursion Pharmaceuticals.

Related Companies

ClinicalTrials.gov is a publicly accessible website and online database of clinical research studies, managed by the National Library of Medicine (NLM) at the National Institutes of Health (NIH). It serves as a central resource for patients, their families, healthcare professionals, and researchers to access comprehensive information on publicly and privately supported clinical studies across a […]

InsightRX provides AI-powered precision medicine software designed to optimize drug therapy from clinical development to the point of care. For physicians and clinical teams, InsightRX offers solutions like InsightRX Nova for Bayesian model-informed dosing, which individualizes drug regimens using validated pharmacokinetic models and real-time patient data. This helps clinicians achieve therapeutic targets more rapidly and […]

Indica Labs is a global leader in AI-powered digital pathology software and services, providing comprehensive solutions for quantitative evaluation and management of whole slide images. Their flagship platforms, HALO® and HALO AI, leverage artificial intelligence and computer vision algorithms to enable fast and precise analysis of tissue samples, which is critical for advancing research and […]

Triomics is an oncology AI company dedicated to transforming how cancer centers manage complex clinical information. The company’s platform utilizes AI agents to meticulously read and interpret comprehensive longitudinal patient records, converting unstructured clinical data—such as notes, pathology reports, imaging results, and genomic panels—into structured, verifiable outputs. This process significantly reduces the manual burden on […]

ClinTrialMatch is an AI-powered digital health platform designed to optimize patient recruitment, enrollment, and retention in clinical trials. The platform aims to bridge the gap between patients seeking treatment options and clinical trials needing participants by leveraging AI-driven insights. It is currently an early-stage platform undergoing development and pilot collaboration. For physicians, ClinTrialMatch offers a […]

Evaxion Biotech is a pioneering clinical-stage TechBio company that leverages its proprietary, clinically validated, and scalable AI platform, AI-Immunology™, to decode the human immune system. This platform is used to discover and develop novel immunotherapies for cancer, infectious diseases, and increasingly, autoimmune diseases. The company’s mission is to transform patients’ lives by providing inventive and […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.